Related references
Note: Only part of the references are listed.Inhaled loxapine for agitation revisited: focus on effect sizes from 2 Phase III randomised controlled trials in persons with schizophrenia or bipolar disorder
L. Citrome
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2012)
Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
L. Citrome
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2012)
Why Do Some Depressed Outpatients Who Are in Remission According to the Hamilton Depression Rating Scale Not Consider Themselves to Be in Remission?
Mark Zimmerman et al.
JOURNAL OF CLINICAL PSYCHIATRY (2012)
Treatments for bipolar disorder: can number needed to treat/harm help inform clinical decisions?
T. A. Ketter et al.
ACTA PSYCHIATRICA SCANDINAVICA (2011)
Clinical Relevance of Treatments for Acute Bipolar Disorder: Balancing Therapeutic and Adverse Effects
Shefali Srivastava et al.
CLINICAL THERAPEUTICS (2011)
Relative vs. absolute measures of benefit and risk: what's the difference?
L. Citrome
ACTA PSYCHIATRICA SCANDINAVICA (2010)
Adjunctive Aripiprazole, Olanzapine, or Quetiapine for Major Depressive Disorder: An Analysis of Number Needed to Treat, Number Needed to Harm, and Likelihood to be Helped or Harmed
Leslie Citrome
POSTGRADUATE MEDICINE (2010)
Quantifying Risk: The Role of Absolute and Relative Measures in Interpreting Risk of Adverse Reactions from Product Labels of Antipsychotic Medications
Leslie Citrome
CURRENT DRUG SAFETY (2009)
Compelling or irrelevant? Using number needed to treat can help decide
L. Citrome
ACTA PSYCHIATRICA SCANDINAVICA (2008)
Antipsychotics for the treatment of schizophrenia: likelihood to be helped or harmed, understanding proximal and distal benefits and risks
Leslie Citrome et al.
Expert Review of Neurotherapeutics (2008)
Understanding the minimum clinically important difference: a review of concepts and methods
Anne G. Copay et al.
SPINE JOURNAL (2007)
Treatment benefits of duloxetine in major depressive disorder as assessed by number needed to treat
John Cookson et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2006)
Size of treatment effects and their importance to clinical research and practice
Helena Chmura Kraemer et al.
BIOLOGICAL PSYCHIATRY (2006)
10-minute consultation - Newly diagnosed hypertension
C A'Court
BMJ-BRITISH MEDICAL JOURNAL (2002)
Share Paper
